Elekta
Elekta AB, commonly known as Elekta, is a leading innovator in the field of medical technology, headquartered in Stockholm, Sweden (SE). Founded in 1972, the company has established itself as a key player in the oncology and neurosurgery sectors, providing advanced solutions for cancer treatment and brain disorders. Elekta's core offerings include state-of-the-art radiation therapy systems, software solutions for treatment planning, and comprehensive patient management tools. What sets Elekta apart is its commitment to precision and personalised care, utilising cutting-edge technology to enhance treatment outcomes. With a strong presence in Europe, North America, and Asia, Elekta has achieved significant milestones, including numerous awards for innovation and excellence in healthcare. The company continues to lead the market, driven by its mission to improve the lives of patients worldwide through advanced medical solutions.
DitchCarbon Score
How does Elekta's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Elekta's score of 74 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Elekta's reported carbon emissions
In 2023, Elekta reported total carbon emissions of approximately 621,713,000 kg CO2e, with Scope 1 emissions at about 6,247,000 kg CO2e, Scope 2 emissions at approximately 3,347,000 kg CO2e, and significant Scope 3 emissions of around 612,119,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by FY2031, using FY2021 as the baseline. Additionally, Elekta plans to increase its annual sourcing of renewable electricity from 61% in FY2021 to 100% by FY2030. Elekta is also focused on reducing Scope 3 emissions, specifically targeting a 55% reduction in emissions associated with the use and end-of-life treatment of sold products per radiotherapy cancer treatment course by FY2031. Furthermore, the company aims for 45% of its suppliers, based on emissions, to have science-based targets by FY2026. These initiatives reflect Elekta's commitment to sustainability and its alignment with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,576,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 444,082,520 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Elekta is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
